Dr. Jack Hu, founder and CEO of Calissa Therapeutics, leverages his extensive experience in finance and biopharma to develop and commercialize a first-in-class therapy for birthmarks and rosacea. Prior to founding Calissa, Dr. Hu served as CFO and CSO of Genor Biopharma, where he raised $560 million in IPO/crossover, and transformed company's pipeline through strategic business development deals. During his earlier career on Wall Street at both buyside and sellside, he was a biotech analyst with Leerink Partners and Oppenheimer, and a Managing Director with Deutsche Bank covering APAC healthcare where he was ranked no.1 by institutional investor. He started his career at Wyeth Biopharma as a marketing manager, and was trained at the University of Texas M.D. Anderson Cancer Center.